Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GALT
GALT logo

GALT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Galectin Therapeutics Inc (GALT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.520
1 Day change
-1.95%
52 Week Range
7.130
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

GALT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a neutral-to-mixed technical setup, no recent news catalyst, no meaningful institutional or insider buying trend, and no strong proprietary buy signal. Given the lack of clear upside confirmation and the absence of financial/valuation support, the best call is to hold off rather than buy immediately.

Technical Analysis

Current price is 2.61, slightly above the previous close of 2.57. The MACD histogram is positive at 0.068 but contracting, which suggests momentum is not accelerating. RSI_6 at 58.694 is neutral, indicating the stock is neither oversold nor overbought. Moving averages are converging, which usually points to a weak trend or potential transition rather than a confirmed uptrend. Key levels show pivot at 2.529, resistance at 2.927 and 3.172, with support at 2.132 and 1.887. Overall, the chart does not show a clean breakout setup. Short-term pattern analysis also projects weak forward performance, with roughly flat next-week movement and a negative one-month bias.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper because both put-call ratios are very low, indicating call-heavy positioning. Call open interest is 20,357 versus put open interest of 2,380, and today’s option volume is also heavily call-skewed at 160 calls versus 8 puts. Implied volatility is high at 140.3, showing this is a speculative name with expensive options. This supports bullish sentiment, but the signal is more trading-oriented than long-term fundamental conviction.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
5

Positive Catalysts

  • ["Call-heavy options positioning suggests bullish trader sentiment.", "Price is trading above the pivot level, which keeps the short-term structure mildly constructive.", "MACD histogram remains positive, indicating some residual upward momentum.", "Pre-market move was positive at 6.67%, showing intermittent buyer interest."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no clear event-driven catalyst.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Insiders are neutral with no significant trading trends over the last month.", "No recent congress trading data available.", "MACD momentum is contracting rather than expanding.", "Moving averages are converging, which weakens trend conviction.", "Analyst and valuation data are not available to support a long-term bullish case.", "Pattern-based outlook suggests negative one-month performance."]

Financial Performance

No usable financial snapshot was provided because of an error, so latest-quarter revenue, earnings, and growth trends could not be assessed. The latest quarter season is therefore unavailable from the data supplied.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of a recent upgrade/downgrade cycle or consensus target shift. Wall Street pros view cannot be confirmed from the dataset, and the absence of analyst support weakens the case for a long-term buy.

Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
Wall Street analysts forecast GALT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.570
sliders
Low
11
Averages
11
High
11
Current: 2.570
sliders
Low
11
Averages
11
High
11
H.C. Wainwright
Matthew Keller
Buy
maintain
$6 -> $11
AI Analysis
2025-12-17
Reason
H.C. Wainwright
Matthew Keller
Price Target
$6 -> $11
AI Analysis
2025-12-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Keller raised the firm's price target on Galectin Therapeutics to $11 from $6 and keeps a Buy rating on the shares. The firm says recent biomarker data continue to strengthen confidence in Galectin's metabolic dysfunction-associated steatohepatitis program.
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$6
2025-06-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$6
2025-06-18
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Galectin Therapeutics with a Buy rating and $6 price target. Galectin's lead asset is belapectin, an intravenously administered galectin-3 inhibitor. Galectin-3 is a protein that plays a key role in cell signaling, differentiation, apoptosis, and inflammation, the analyst tells investors in a research note. The firm says that despite the company's setbacks, it believes "the stock can get back on track." It says belapectin is a "unique therapy targeting a clinically relevant molecule."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GALT
Unlock Now

People Also Watch